About US
Contact us
-
After Roche, BMS surprises, what does AbbVie need to do to win FTC clearance for Allergan buy?With mergers and acquisitions come antitrust reviews. And withthe U.S. Federal Trade Commission (FTC) cracking down on pharma deals these days, it’s only natural to ask whether AbbVie’s proposed $632019/6/25
-
On the road: Acadia teams up with Michael J. Fox Foundation for local, patient-focused Parkinson's eventsAcadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation. The “Parkinson’s IQ + You”serieswill traverse the country through this2019/6/25
-
Former Pfizer site in Puerto Rico picked up by medical marijuana producerLooks like unloading surplus manufacturing sites to the cannabis industry is turning into a budding business for pharma. At the same time Novartis was negotiating a deal to sell a Colorado plant to a2019/6/24
-
Lilly enlists patients to raise cluster headache awareness after Emgality scores second nodCluster headache pain is so intense, one patient describes banging his head against the refrigerator door to make it stop. And he's justone of severalpatientsdescribing the agitating pain of episodic2019/6/24
-
Allergan, following years of turmoil and resistance, heads for split: analystAllergan has grappled with numerous setbacks and plenty of investor uproar in recent years, but so far it's resisted serious change. But now, the company seems ready to embark on a split, according2019/6/21
-
Ironwood, Allergan's new Linzess pain data could cue much-needed prescription jumpIronwood and Allergan have long pinned hopes for IBS drug Linzess on getting patients to switch from over-the-counter remedies to treat constipation. New pain and bloating data for Linzess could help2019/6/21
-
Amphastar squeezes partners Momenta, Sandoz for $60M in Lovenox settlementSanofi’s big-selling blood thinner Lovenox has long faced generic competition in the U.S., but now rival generics makers are squashing long-running lawsuits over their own versions of the drug. Part2019/6/20
-
AstraZeneca's COPD triplet Breztri, rival to GSK's Trelegy, nabs first nod from JapanAs AstraZeneca tussles with British compatriot GlaxoSmithKline in the respiratory arena, it has nabbed its first global approval for Breztri Aerosphere, a three-in-one COPD inhaler that could rival G2019/6/20
-
Merck scouts replacements for CEO Frazier less than a year after scrapping retirement rule: reportIt was less than a year ago that Merck’s board scrapped a policy that CEOs must retire at the age of 65 in a move designed to keep Ken Frazier around longer. Now, the company is scouting replacemen2019/6/19
-
Roche's Floodlight MS app mines 'hidden' data to advance disease mappingCANNES, FRANCE—Multiple sclerosis symptoms can be confusing: They differ person to person, and even day to day for the same patients. Roche's Floodlight Open app aims to clear that confusion for indi2019/6/19